REGN Factor-Based Stock Analysis

Validea's analysis of Regeneron Pharmaceuticals (REGN) indicates it scores 71% using the Benjamin Graham Value Investor model, its highest rating among 22 strategies. While the large-cap growth stock passes criteria for sales, debt, and long-term EPS growth, it notably fails the P/E and Price/Book ratio tests, placing its overall score below the 80% threshold typically signaling investment interest from this deep value methodology.

Analysis

Regeneron Pharmaceuticals (REGN) presents a bifurcated profile according to Validea's Benjamin Graham-based model, scoring 71%, a rating that is its highest among 22 strategies but falls short of the 80% threshold typically signaling interest from this deep value framework. The analysis confirms REGN's robust operational health, as the large-cap biotech firm passes fundamental criteria for sales, current ratio, long-term EPS growth, and maintaining low long-term debt relative to net current assets. However, the core conflict for a value-oriented approach arises from its valuation, with the stock explicitly failing the P/E and Price/Book ratio tests. This indicates that while the company is fundamentally sound, its current market price is not considered cheap by classic value investing standards, a finding consistent with the neutral tone and mildly positive sentiment score.

Key Decisions for Investors

• Strict value investors should exercise caution, as REGN's failure on the critical P/E and Price/Book valuation metrics makes it an unsuitable candidate under the Graham methodology despite its strong operational health.
• Growth-oriented investors might interpret the strong fundamentals, particularly the solid long-term EPS growth, as a justification for the premium valuation, warranting further analysis of its specific growth catalysts.
• Given the valuation disconnect, it may be prudent to place REGN on a watchlist and monitor for a share price pullback that could bring its valuation multiples to more attractive levels, potentially creating a more compelling entry point.